What is Epigenomics?
Epigenomics is a molecular diagnostics firm dedicated to the development and commercialization of blood-based cancer detection products. Leveraging its proprietary DNA methylation biomarker technology, the company targets indications with high unmet medical needs. Its lead product, Epi proColon, is an FDA-approved blood-based screening test for colorectal cancer, available in the United States, Europe, China, and other select markets. The company is also developing Epi proLung(R), a similar blood-based test for lung cancer detection, aiming to revolutionize early cancer diagnosis through accessible and non-invasive methods.
How much funding has Epigenomics raised?
Epigenomics has raised a total of $168.5M across 12 funding rounds:
Stock Offering
$51.5M
Share Placement
$5.3M
Multiple Rounds
$15.2M
Debt
$7M
Share Placement
$6M
Share Placement
$24.3M
Share Placement
$8.2M
Share Placement
$4.4M
Stock Issuance/Offering (2004): $51.5M, investors not publicly disclosed
Share Placement (2014): $5.3M featuring BioChain Institute
Share Placement (2016): $7.4M backed by BioChain Institute
Share Placement (2016): $5.5M with participation from BioChain and UChip Technology
Share Placement (2016): $2.3M led by Cathay Fortune International Company Limited
Debt (2017): $7M, investors not publicly disclosed
Share Placement (2017): $6M, investors not publicly disclosed
Share Placement (2018): $24.3M, investors not publicly disclosed
Share Placement (2019): $8.2M, investors not publicly disclosed
Share Placement (2020): $4.4M, investors not publicly disclosed
Key Investors in Epigenomics
MPM Capital
MPM Capital is a venture capital firm that manages early-stage venture funds, private/public impact funds, and a public equities fund, focusing on converting scientific breakthroughs into therapeutics for patients in need.
Abingworth
Abingworth is a transatlantic life sciences investment firm that supports companies developing novel medicines by providing capital and expertise, with a focus on seed, early-stage, development-stage, and clinical co-development investments.
3i Group
3i Group is an investment company specializing in Private Equity and Infrastructure, focusing on mid-market companies in northern Europe and North America.
What's next for Epigenomics?
With the recent major strategic investment and substantial overall capital raised, Epigenomics is poised to accelerate its product development pipeline and expand its market reach. The company's focus on blood-based diagnostics for prevalent cancers like colorectal and lung cancer positions it to capitalize on the growing demand for less invasive and more effective screening solutions. Future endeavors will likely involve further clinical validation, regulatory approvals in new territories, and scaling commercialization efforts to make its diagnostic technologies widely accessible to patients and healthcare providers worldwide.
See full Epigenomics company page
